Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs
Related Experiment Video
Updated: Aug 16, 2026

Detecting Anastasis In Vivo by CaspaseTracker Biosensor
Published on: February 1, 2018
Michelle D Althuis1, Bert Scoccia, Emmet J Lamb
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Objective:
This study was undertaken to evaluate melanoma, thyroid, colon, and cervical cancer risks after clomiphene or gonadotropins.
Study Design:
Retrospective cohort of 8422 women (155,527 women-years) evaluated for infertility (1965-1988). Through 1999, cancers were ascertained by questionnaire, cancer and death registries. Poisson regression estimated adjusted rate ratios (RRs).
Results:
Clomiphene use did not significantly increase risk of melanoma (RR=1.66; 95% CI, 0.9-3.1), thyroid (RR=1.42; 95% CI, 0.5-3.7), cervical (RR=1.61; 95% CI, 0.5-4.7), or colon cancer (RR=0.83; 95% CI, 0.4-1.9). We found no relationship between clomiphene dose or cycles of use and cancer risk at any site. Clomiphene use may impart stronger effects on risks of melanoma (RR=2.00; 95% CI, 0.9-4.6) and thyroid cancer among women who remained nulliparous (RR=4.23; 95% CI, 1.0-17.1). Gonadotropins did not increase cancer risk for these sites.
Conclusion:
Fertility drugs do not appear to have strong effects on these cancers. Nonetheless, follow-up should be pursued to assess long-term risks and to monitor effects among women who remain nulliparous.
Related Concept Videos
Teratogenicity
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Spermatogenesis
Drug Toxicity: Risk factors
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Mutagenicity and Carcinogenicity